Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chubb
Chinese Patent Office
Julphar
Healthtrust
US Department of Justice

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 8,748,577

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,748,577
Title:Conjugates of biologically active polypeptides having an increased in vivo half-life
Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
Inventor(s): Besman; Marc (Seattle, WA), Chipman; Stewart (Bainbridge Island, WA), Leung; David (Mercer Island, WA), Singer; Jack (Seattle, WA)
Assignee: Cell Therapeutics, Inc. (Seattle, WA)
Application Number:13/363,278
Patent Claims:see list of patent claims

Details for Patent 8,748,577

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX search
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX search
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24 ➤ Sign Up Cell Therapeutics, Inc. (Seattle, WA) 2025-08-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Harvard Business School
Federal Trade Commission
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.